Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting

Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of…

read more

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg…

read more

Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients

The results of this landmark study should be welcomed news to cancer patients across the…

read more

Counterpoints: To Transplant or Not To Transplant

More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is…

read more

Multiple Myeloma: ‘Old Rules’ No Longer Apply

Original Article Writen by: Robert Carlson – Oncology Times NEW YORK—Treatment regimens for relapsed/refractory multiple…

read more

An Overview of Progress in Myeloma Research with Dr. James Berenson

Myeloma news from the 2014 annual meeting of the American Society of Clinical Oncology has…

read more

ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma

Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US…

read more

Tommy Garceau, IMBCR’s Marathon Team Captain

Tommy, who has been Dr. Berenson’s able assistant for many years, has a passion for…

read more

Talking About Myeloma with Loved Ones

Do you feel the Love? The New Year is here. Perhaps you have been newly…

read more

Counterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment?

By Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma…

read more